CL2008002523A1 - Metodo para lograr un efecto anestesico limitado en un sujeto, que comprende administrar a dicho sujeto un antagonista del receptor de glutamato nmda y administrar a dicho sujeto un anestesico general; combinacion que comprende un antagonista del rec - Google Patents

Metodo para lograr un efecto anestesico limitado en un sujeto, que comprende administrar a dicho sujeto un antagonista del receptor de glutamato nmda y administrar a dicho sujeto un anestesico general; combinacion que comprende un antagonista del rec

Info

Publication number
CL2008002523A1
CL2008002523A1 CL200802523A CL2008002523A CL2008002523A1 CL 2008002523 A1 CL2008002523 A1 CL 2008002523A1 CL 200802523 A CL200802523 A CL 200802523A CL 2008002523 A CL2008002523 A CL 2008002523A CL 2008002523 A1 CL2008002523 A1 CL 2008002523A1
Authority
CL
Chile
Prior art keywords
administer
antagonist
subject
anesthetic
achieving
Prior art date
Application number
CL200802523A
Other languages
English (en)
Inventor
Cecil Mark Muir William Eppler
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39797439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CL2008002523A1 publication Critical patent/CL2008002523A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CL200802523A 2007-08-27 2008-08-27 Metodo para lograr un efecto anestesico limitado en un sujeto, que comprende administrar a dicho sujeto un antagonista del receptor de glutamato nmda y administrar a dicho sujeto un anestesico general; combinacion que comprende un antagonista del rec CL2008002523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96823607P 2007-08-27 2007-08-27

Publications (1)

Publication Number Publication Date
CL2008002523A1 true CL2008002523A1 (es) 2008-10-10

Family

ID=39797439

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200802523A CL2008002523A1 (es) 2007-08-27 2008-08-27 Metodo para lograr un efecto anestesico limitado en un sujeto, que comprende administrar a dicho sujeto un antagonista del receptor de glutamato nmda y administrar a dicho sujeto un anestesico general; combinacion que comprende un antagonista del rec

Country Status (14)

Country Link
US (1) US20090061024A1 (es)
EP (1) EP2195031A1 (es)
JP (1) JP2010537999A (es)
KR (1) KR20100049663A (es)
CN (1) CN101896205A (es)
AR (1) AR068350A1 (es)
AU (1) AU2008293622A1 (es)
BR (1) BRPI0815821A2 (es)
CA (1) CA2697739A1 (es)
CL (1) CL2008002523A1 (es)
MX (1) MX2010002191A (es)
TW (1) TW200918077A (es)
WO (1) WO2009029618A1 (es)
ZA (1) ZA201001252B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110139274A (ko) 2009-03-19 2011-12-28 와이어쓰 엘엘씨 ［2-(8,9-다이옥소-2,6-다이아자바이사이클로［5.2.0］논-1(7)-엔-2-일)에틸］포스폰산 및 이의 전구체의 제조 방법
US11083696B2 (en) * 2011-09-21 2021-08-10 University College Cardiff Consultants Limited Dispersion anaesthetic device
EP4032533A1 (en) 2012-07-10 2022-07-27 The Regents of The University of California Methods of inducing anesthesia
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
WO2015149066A1 (en) * 2014-03-28 2015-10-01 University Of Virginia Patent Foundation General anesthetics that are not neurotoxic
WO2015187918A2 (en) 2014-06-05 2015-12-10 The Regents Of The University Of California Halogenated ether compounds and methods of inducing anesthesia
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en) * 2015-06-19 2019-08-27 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
CN106109468A (zh) * 2016-07-11 2016-11-16 孙剑 一种女性发育期注射麻醉剂
CN106166159A (zh) * 2016-07-11 2016-11-30 孙剑 一种复方注射麻醉剂
CN106176770A (zh) * 2016-07-11 2016-12-07 孙剑 一种男性发育期注射麻醉剂
CN109794292B (zh) * 2019-01-10 2021-12-07 天津大学 Z-选择性钌卡宾烯烃复分解催化剂及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US7089200B2 (en) * 1999-12-21 2006-08-08 Third Millennium Management Pty Ltd Payroll management method and apparatus
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
AU2004230895B2 (en) * 2003-04-09 2010-09-09 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as N-methyl-D-aspartate (NMDA) receptor antagonists
CN1802161A (zh) * 2003-04-09 2006-07-12 惠氏公司 [2－(8,9－二氧代－2,6－二氮杂双环[5.2.0]壬－1(7)－烯－2－基)烷基]－膦酸及其衍生物的鼻内给药药用组合物及用法
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
KR20070100233A (ko) * 2004-10-08 2007-10-10 와이어쓰 [2-(8,9-디옥소-2,6-디아자바이사이클로[5.2.0]논-1(7)-엔-2-일)알킬]포스폰산의 유도체 및 이의 제조 방법

Also Published As

Publication number Publication date
CA2697739A1 (en) 2009-03-05
AU2008293622A1 (en) 2009-03-05
CN101896205A (zh) 2010-11-24
AR068350A1 (es) 2009-11-11
ZA201001252B (en) 2011-04-28
TW200918077A (en) 2009-05-01
KR20100049663A (ko) 2010-05-12
WO2009029618A1 (en) 2009-03-05
MX2010002191A (es) 2010-03-17
BRPI0815821A2 (pt) 2015-02-18
US20090061024A1 (en) 2009-03-05
EP2195031A1 (en) 2010-06-16
JP2010537999A (ja) 2010-12-09

Similar Documents

Publication Publication Date Title
CL2008002523A1 (es) Metodo para lograr un efecto anestesico limitado en un sujeto, que comprende administrar a dicho sujeto un antagonista del receptor de glutamato nmda y administrar a dicho sujeto un anestesico general; combinacion que comprende un antagonista del rec
LTPA2020005I1 (lt) Dozavimo schema S1P receptoriaus agonistui
BRPI0812136A2 (pt) aparelhos, sistemas e métodos para determinar o uso complacente d eum aparelho oral.
BRPI0911614A2 (pt) técnicas para gerenciar um quadro de comunicações para eventos de conferência multimídia.
BRPI0918994A2 (pt) dispositivo, e, método para transmitir um sinal de áudio para um usuário.
BRPI0923801A2 (pt) Métodos para produzir um éster, e para produzir amidas.
DK2152250T3 (da) Faste doseringsformer, der omfatter et enterisk overtræk, med accelereret lægemiddelfrigivelse
EP2419870A4 (en) SYSTEMS, METHODS AND SUPPORTS FOR INVESTIGATION MANAGEMENT
CL2012003162A1 (es) Formulacion farmaceutica de administracion oral que comprende un compuesto derivado de 1-(beta-d-glucopiranosil)-3-(2-tienilmetil)benceno sustituido, un diluyente , un desintegrante, un aglutinante y un lubricante; composición farmaceutica; y metodo para tratar un trastorno mediado por transportadores de glucosa dependientes de sodio.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0909061A2 (pt) Arranjo de unidade para uma disposição de alto-falantes, disposição de alto-falantes, sistema de som circundante, e, métodos para prover um arranjo de unidade para uma disposição de alto-falantes.
MX2010000724A (es) Metodo para reducir presion intracraneal.
MX2013002430A (es) Formas de dosis de disolucion de rápida de agonistas de 5-ht2c.
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
BR112012001959A2 (pt) comprimido,e, método para reproduzir um comprimido
CL2007003817A1 (es) Agente terapeutico para la miopatia inflamatoria que comprende un antagonista de interleucina-6 (il-6).
BRPI0917345A2 (pt) composição, e, método para produzir uma composição estabilizada.
GB0903564D0 (en) Apparatus for managing attribute information on system resources
BRPI0909491A2 (pt) método e sistema para permitir múltiplas unidades de recebimento em uma rede para gravar o mesmo conteúdo enquanto minimiza o uso de recurso de rede
HU0800265D0 (en) X-ray device, diaphragm for the x-ray device and method for generating picture information with the x-ray device
EP2530290A4 (en) Method for determining fuel quality, program, computer readable recording medium having the program stored thereupon, and device for determining fuel quality
BR112012002388A2 (pt) método de fornecimento de conteúdo realizado através de uma rede, método para receber conteúdo realizado através de uma rede, dispositivo para fornecer conteúdo através de uma rede, e, dispositivo para receber conteúdo para recebimento de conteúdo através de uma rede.
MX2010002193A (es) Metodo de determinacion de actividad pdh y generacion de imagen para su uso en dicho metodo.
BRPI0822889A2 (pt) Dispositivo anti-retorno, e, método para testar a integridade operacional de um dispositivo anti-retorno.
BRPI0912223A2 (pt) métodos para melhorar funcionamento cognitivo e para tratar uma doença, composto, uso do mesmo, e, composição farmacêutica.